

<u>Business name</u>	<u>In cooperation with</u>	<u>Products marketed</u>	<u>Future trends</u>
	Assistant Professor Hideo Inoko Professor Kimiyoishi Tsuji	Typing of HLA is being performed. But the market is small and was approximately 6,000,000 yen for 150 items in 1988. There is no tendency toward an increase and further expansion is doubtful.	are currently receiving 40,000 yen for 1 item, and do not employ probes with RFLP for evaluation by pattern recognition. The cost will thereby become 1/4. 2) Selling in Japan of mainly probes for infectious disease has also been attempted in the past by foreign venture businesses at Nichirei. As yet, studies have not been completed on rapid diagnosis and mother-child infections. These will be considered in the future after studies have been performed. These are regarded as <u>in-vitro</u> diagnostic drugs.
Toyo Boseki	Molecular Biosystems Dupont (U.S.) Import and selling of products	At the present time, the following probes are used as research reagents: 1. HBV 2. HSV 3. campylobacter 4. enterorirus 5. HIV 6. rotavirus 7. malaria Moreover, Taq polymerase related to PCR is also on the market.	1) The use of DNA probe diagnosis will emphasize confirmation diagnosis. HIV and ATL use definite diagnosis. Identification of pathogens of diarrhea may be employed for choice of antibiotics. 2) How to clinically use <u>in-vitro</u> diagnostic drugs will be in line with the policy of each company. Products that show superior specificity for an item will probably not be marketed as <u>in-vitro</u> diagnostic drugs.
Takara-shuzo	Organics Ltd., (Israel) "Chemiprobe" Product import Perkin-Elmer Co. Amplification device by PCR method	Import and selling of 16 items for cancer genes is being performed by Organics PCR amplification device has been	1) PCR is necessary in DNA probe diagnosis. Improvement of sensitivity is expected and this is expected to be the future basis for treatment in clinical laboratories. 2) Infectious diseases are the main target. However, conventional